ALB and hepatocellular carcinoma: Another study conducted by Lee et al. [105] verified an independent association between a high post-treatment serum ALB–BIL grade and worse post-progression survival (PPS) in HCC patients who received molecular targeted therapy with sorafenib and developed progressive disease (PD).